AbbVie’s Immunology Growth Strategy Is Delivering, But Imbruvica Reduced By IRA

 
• By Joseph Haas

AbbVie’s $2.1bn write down of Imbruvica’s value is tied directly to Medicare drug price negotiations. Humira’s US biosimilar erosion continued as projected, while the Skyrizi/Rinvoq duo are set to top Humira peak sales by 2027.

Writeoff
AbbVie has written down Imbruvica's value by $2.1bn • Source: Shutterstock

More from Earnings

More from Business